Yolanda García, T. Gorp, Gottfried E Konecny, Alexandra Leary, Alessandro D Santin, Shanthini M. Crusz, Gina Mantia-Smaldone, Domenica Lorusso, N. Colombo, J. Thomes-Pepin, Andrzej Roszak, P. Ottevanger, Mario Beiner, David Cibula, Charles Leath, Lingling Li, Michael Method, Kathleen N Moore
{"title":"360 接受米韦妥昔单抗与研究者选择的化疗的 FRα 阳性铂类耐药卵巢癌患者的健康相关生活质量:MIRASOL 3 期试验分析","authors":"Yolanda García, T. Gorp, Gottfried E Konecny, Alexandra Leary, Alessandro D Santin, Shanthini M. Crusz, Gina Mantia-Smaldone, Domenica Lorusso, N. Colombo, J. Thomes-Pepin, Andrzej Roszak, P. Ottevanger, Mario Beiner, David Cibula, Charles Leath, Lingling Li, Michael Method, Kathleen N Moore","doi":"10.1136/ijgc-2024-esgo.43","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"412 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"360 Health-related quality of life in patients with FRα positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs. investigator’s choice chemotherapy: analysis from the phase 3 MIRASOL trial\",\"authors\":\"Yolanda García, T. Gorp, Gottfried E Konecny, Alexandra Leary, Alessandro D Santin, Shanthini M. Crusz, Gina Mantia-Smaldone, Domenica Lorusso, N. Colombo, J. Thomes-Pepin, Andrzej Roszak, P. Ottevanger, Mario Beiner, David Cibula, Charles Leath, Lingling Li, Michael Method, Kathleen N Moore\",\"doi\":\"10.1136/ijgc-2024-esgo.43\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"412 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.43\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.43","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
360 Health-related quality of life in patients with FRα positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs. investigator’s choice chemotherapy: analysis from the phase 3 MIRASOL trial